아이젠멘거 증후군 관리 시장 예측(-2032년) : 약제 유형, 치료법, 진단, 환자 연령층, 유통 채널, 최종사용자, 지역별 세계 분석

According to Stratistics MRC, the Global Eisenmenger Complex Management Market is accounted for $1.36 billion in 2025 and is expected to reach $2.82 billion by 2032 growing at a CAGR of 11.0% during the forecast period. Eisenmenger complex management is a multidisciplinary approach that aims to improve quality of life, prevent complications, and alleviate symptoms because pulmonary vascular disease is usually irreversible once it has advanced. Oxygen therapy and pulmonary vasodilators like phosphodiesterase-5 inhibitors, endothelin receptor antagonists, and prostacyclin analogs are all part of medical management to lower pulmonary arterial pressure. Moreover, high altitudes, dehydration, and vigorous physical activity are discouraged for patients. Severe hyperviscosity symptoms can sometimes be treated with phlebotomy, and iron deficiency needs to be treated. The only cure in more severe cases is still heart-lung or lung transplantation, frequently combined with repair of the cardiac defect.

According to data from the Pulmonary Hypertension Association, up to 40 % of congenital heart disease (CHD) patients have cardiac defects that predispose them to pulmonary hypertension (PH), and approximately 10 % of these patients actually develop PH. In regions with limited access to care, up to 30 % of patients with unrepaired CHD progress to Eisenmenger syndrome.

Market Dynamics:

Driver:

Increased congenital heart disease (CHD) prevalence

With an incidence rate of roughly 9-10 per 1,000 live births, congenital heart diseases continue to rank among the most prevalent birth defects worldwide, according to the World Health Organization (WHO). Large septal defects in particular have the potential to cause pulmonary vascular remodeling and increased pulmonary blood flow. They develop into Eisenmenger syndrome if they are not treated. Additionally, Eisenmenger-specific management strategies are becoming more and more necessary as more undiagnosed CHD cases are discovered later in life as healthcare systems in low- and middle-income nations continue to advance their diagnostic capabilities.

Restraint:

Restricted options for curative treatment

Eisenmenger syndrome is still mostly irreversible once pulmonary vascular remodeling is established, even with improvements in treatment. The majority of modern therapies are palliative in nature, concentrating on managing symptoms rather than stopping the progression of the illness. Due to long-term immunosuppression problems, surgical risks, and donor shortages, curative procedures such as lung or heart transplantation are uncommon. Furthermore, this lack of conclusive treatment options limits the market's ability to shift from supportive to curative care models and limits patient outcomes.

Opportunity:

Innovation in disease-specific medicines

Currently, the majority of drugs used to treat Eisenmenger syndrome are modified versions of those used to treat idiopathic pulmonary arterial hypertension (IPAH). Eisenmenger's distinct pathophysiology presents a great opportunity for the development of disease-specific treatments, especially in light of the cyanotic state, right-to-left shunting, and hyperviscosity problems. Improved clinical outcomes and quality of life may result from novel agents that more precisely address endothelial dysfunction, hypoxemia, or microvascular remodeling. Moreover, the designation of orphan drugs and expedited regulatory processes for rare diseases further entice biotech innovation.

Threat:

Rivalry with other priorities for rare diseases

Higher-profile or more common orphan diseases like spinal muscular atrophy, muscular dystrophies, or cystic fibrosis may compete for funding for Eisenmenger syndrome as pharmaceutical companies and global healthcare systems place a greater emphasis on rare diseases. Research funding, grants, and commercial investment are more likely to be allocated to conditions with stronger patient registries, advocacy networks, and biomarker development. Additionally, Eisenmenger syndrome may therefore find it difficult to get attention in rare disease pipelines, which would impede clinical trials and medication development.

Covid-19 Impact:

The COVID-19 pandemic had a major effect on the Eisenmenger Complex Management Market because it delayed elective surgeries, interfered with regular healthcare services, and restricted access to specialized care facilities-all of which are necessary for managing this complicated illness. Numerous Eisenmenger patients, who are already at high risk because of underlying cardiopulmonary compromise, were more susceptible to serious COVID-19 consequences, which increased the need for home-based monitoring and telemedicine. However, the pandemic also hastened the adoption of remote consultations and digital health tools and increased awareness of cardiovascular and chronic respiratory conditions, which has led to long-term opportunities for enhancing post-pandemic disease management infrastructure.

The endothelin receptor antagonists segment is expected to be the largest during the forecast period

The endothelin receptor antagonists segment is expected to account for the largest market share during the forecast period. These medications, like bosentan and ambrisentan, have been clinically shown to increase exercise tolerance, lower pulmonary vascular resistance, and improve quality of life in Eisenmenger syndrome patients. Since the endothelin pathway is a major contributor to pulmonary arterial hypertension (PAH), they are very effective at controlling symptoms and delaying the course of the disease. Since they are effective, have proven safety profiles, and are becoming more widely available worldwide under orphan drug frameworks, these medications are highly recommended by international guidelines and control the treatment landscape.

The cardiac catheterization segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the cardiac catheterization segment is predicted to witness the highest growth rate. The severity and course of Eisenmenger syndrome can be evaluated with the help of this diagnostic procedure, which offers accurate and direct measurements of pulmonary artery pressure, vascular resistance, and shunt magnitude. The need for invasive hemodynamic evaluation to direct targeted therapies has grown as treatment regimens become more customized. Safety and accuracy have been improved by technological developments, such as the incorporation of real-time imaging and better catheter-based instruments. Furthermore, it is a major growth driver in advanced Eisenmenger diagnostics due to its role in pre-transplant evaluation and research trials, which reinforces its adoption.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, mainly because of its sophisticated pulmonary hypertension treatments, high awareness of congenital heart conditions, and well-established healthcare system. Strong insurance coverage for rare diseases, specialized adult congenital heart disease (ACHD) centers, and top pharmaceutical companies all contribute to the region's advantages. Moreover, active clinical research and robust backing from advocacy groups such as the Pulmonary Hypertension Association (PHA) support early diagnosis and optimal care. Therapeutic innovation and market expansion in North America are further supported by favorable regulatory pathways, such as the FDA's designation of orphan drugs.

Region with highest CAGR:

Over the forecast period, the Asia-Pacific region is anticipated to exhibit the highest CAGR, driven by growing access to cutting-edge diagnostics and treatments, growing healthcare spending, and growing awareness of congenital cardiac conditions. Through the use of digital healthcare tools and public health initiatives, nations such as China, Japan, and India are enhancing their capacity for early diagnosis. A sizable population is at risk because of the rising prevalence of untreated congenital heart defects brought on by high birth rates and historically restricted access to pediatric cardiac care. Additionally, the entry of foreign pharmaceutical companies and government assistance for rare disease initiatives are also speeding up the region's market expansion.

Key players in the market

Some of the key players in Eisenmenger Complex Management Market include Bayer AG, Gilead Sciences Inc., Actelion Pharmaceuticals Ltd, Merck and Co., Inc., Novartis AG, AstraZeneca plc., Pfizer, Inc., Teva Pharmaceutical Industries Ltd. and United Therapeutics Corporation.

Key Developments:

In March 2025, Merck and Jiangsu Hengrui Pharmaceuticals Co., Ltd. announced that the companies have entered into an exclusive license agreement for HRS-5346, an investigational oral small molecule Lipoprotein(a), or Lp(a), inhibitor currently being evaluated in a Phase 2 clinical trial in China. Under the agreement, Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region.

In January 2025, Bayer announced that the company has signed a new exclusive distribution agreement with UK-based Ecospray to market a biological liquid nematicide sourced from garlic. The product presents a biological alternative to traditional synthetic chemical nematicides in vegetable and potato crops, and will be marketed in the European Union under the new name Velsinum(TM).

In December 2024, Gilead Sciences, Inc. and Tubulis announced that they have entered into an exclusive option and license agreement to discover and develop an antibody-drug conjugate (ADC) against a solid tumor target. Through this agreement, Gilead will gain access to Tubulis' proprietary Tubutecan and Alco5 platforms.

Drug Types Covered:

• Antiarrhythmic Agents
• Blood Thinning Agents
• Endothelin Receptor Antagonists
• Pulmonary Vasodilators
• Other Drug Types

Therapies Covered:

• Oxygen Therapy
• Medical Management
• Surgical Interventions
• Pulmonary Rehabilitation
• Supportive Care

Diagnosis Covered:

• Blood Tests
• Chest X-ray
• Echocardiogram (Echo)
• Electrocardiogram (ECG)
• Computed Tomography (CT)
• Magnetic Resonance Imaging (MRI)
• Cardiac Catheterization

Patient Age Groups Covered:

• Pediatric
• Adult
• Geriatric

Distribution Channels Covered:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

End Users Covered:

• Hospitals
• Specialized Cardiac Centers
• Diagnostic Laboratories

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 End User Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Eisenmenger Complex Management Market, By Drug Type

• 5.1 Introduction
• 5.2 Antiarrhythmic Agents
• 5.3 Blood Thinning Agents
• 5.4 Endothelin Receptor Antagonists
• 5.5 Pulmonary Vasodilators
• 5.6 Other Drug Types

6 Global Eisenmenger Complex Management Market, By Therapy

• 6.1 Introduction
• 6.2 Oxygen Therapy
• 6.3 Medical Management
• 6.4 Surgical Interventions
• 6.5 Pulmonary Rehabilitation
• 6.6 Supportive Care

7 Global Eisenmenger Complex Management Market, By Diagnosis

• 7.1 Introduction
• 7.2 Blood Tests
• 7.3 Chest X-ray
• 7.4 Echocardiogram (Echo)
• 7.5 Electrocardiogram (ECG)
• 7.6 Computed Tomography (CT)
• 7.7 Magnetic Resonance Imaging (MRI)
• 7.8 Cardiac Catheterization

8 Global Eisenmenger Complex Management Market, By Patient Age Group

• 8.1 Introduction
• 8.2 Pediatric
• 8.3 Adult
• 8.4 Geriatric

9 Global Eisenmenger Complex Management Market, By Distribution Channel

• 9.1 Introduction
• 9.2 Hospital Pharmacies
• 9.3 Retail Pharmacies
• 9.4 Online Pharmacies

10 Global Eisenmenger Complex Management Market, By End User

• 10.1 Introduction
• 10.2 Hospitals
• 10.3 Specialized Cardiac Centers
• 10.4 Diagnostic Laboratories

11 Global Eisenmenger Complex Management Market, By Geography

• 11.1 Introduction
• 11.2 North America
  • 11.2.1 US
  • 11.2.2 Canada
  • 11.2.3 Mexico
• 11.3 Europe
  • 11.3.1 Germany
  • 11.3.2 UK
  • 11.3.3 Italy
  • 11.3.4 France
  • 11.3.5 Spain
  • 11.3.6 Rest of Europe
• 11.4 Asia Pacific
  • 11.4.1 Japan
  • 11.4.2 China
  • 11.4.3 India
  • 11.4.4 Australia
  • 11.4.5 New Zealand
  • 11.4.6 South Korea
  • 11.4.7 Rest of Asia Pacific
• 11.5 South America
  • 11.5.1 Argentina
  • 11.5.2 Brazil
  • 11.5.3 Chile
  • 11.5.4 Rest of South America
• 11.6 Middle East & Africa
  • 11.6.1 Saudi Arabia
  • 11.6.2 UAE
  • 11.6.3 Qatar
  • 11.6.4 South Africa
  • 11.6.5 Rest of Middle East & Africa

12 Key Developments

• 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 12.2 Acquisitions & Mergers
• 12.3 New Product Launch
• 12.4 Expansions
• 12.5 Other Key Strategies

13 Company Profiling

• 13.1 Bayer AG
• 13.2 Gilead Sciences Inc.
• 13.3 Actelion Pharmaceuticals Ltd
• 13.4 Merck and Co., Inc.
• 13.5 Novartis AG
• 13.6 AstraZeneca plc.
• 13.7 Pfizer, Inc.
• 13.8 Teva Pharmaceutical Industries Ltd.
• 13.9 United Therapeutics Corporation